Contemporary Applications of Machine Learning for Device Therapy in Heart Failure.

cardiac resynchronization therapy echocardiography heart failure left ventricular assist device machine learning transcatheter edge-to-edge repair

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
09 2022
Historique:
received: 23 05 2022
revised: 31 05 2022
accepted: 16 06 2022
entrez: 1 9 2022
pubmed: 2 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

Despite a better understanding of the underlying pathogenesis of heart failure (HF), pharmacotherapy, surgical, and percutaneous interventions do not prevent disease progression in all patients, and a significant proportion of patients end up requiring advanced therapies. Machine learning (ML) is gaining wider acceptance in cardiovascular medicine because of its ability to incorporate large, complex, and multidimensional data and to potentially facilitate the creation of predictive models not constrained by many of the limitations of traditional statistical approaches. With the coexistence of "big data" and novel advanced analytic techniques using ML, there is ever-increasing research into applying ML in the context of HF with the goal of improving patient outcomes. Through this review, the authors describe the basics of ML and summarize the existing published reports regarding contemporary applications of ML in device therapy for HF while highlighting the limitations to widespread implementation and its future promises.

Identifiants

pubmed: 36049812
pii: S2213-1779(22)00410-3
doi: 10.1016/j.jchf.2022.06.011
pii:
doi:

Substances chimiques

Cardiovascular Agents 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

603-622

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al’Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Nitesh Gautam (N)

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Sai Nikhila Ghanta (SN)

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Alex Clausen (A)

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Prachi Saluja (P)

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Kalai Sivakumar (K)

Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Gaurav Dhar (G)

Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Qi Chang (Q)

Department of Computer Science, Rutgers University, The State University of New Jersey, Newark, New Jersey, USA.

Deeptankar DeMazumder (D)

University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Mark G Rabbat (MG)

Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA.

Stephen J Greene (SJ)

Department of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.

Marat Fudim (M)

Department of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.

Subhi J Al'Aref (SJ)

Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Electronic address: sjalaref@uams.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH